First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

Phase 1 Unknown 68 enrolled 1200 Pharma, LLC Translational Research in Oncology · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.

Timeline

Start: 2021-12-23
Primary completion: 2024-12-15
Completion: 2025-12-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UCT-03-008	Unknown	—	Oral

Indications

No indication recorded.